RxDoctor Payments DataLook up a doctor →

Ralph Cahaly, MD

Allergy · Milford, MANPI 1790778553

Payments from drug & device makers

$30,044in general payments, 2019–2025

Across 1,168 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Genentech USA, Inc.$6K
  • Regeneron Healthcare Solutions, Inc.$2K
  • GSK$2K
  • Novartis$1K
  • CSL Behring$1K
  • plus $11K from 36 others

What the payments were for

  • Consulting fees$4,62515%
  • Travel & lodging$8063%
  • Food & beverage$24,28881%
  • Education$3251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,044 in reported general payments places this provider in the 95th percentile of 21 allergy providers in Massachusetts.

See all allergy providers in Massachusetts

Medicare billing

Part B allowed, 2024
$145,343
Medicare patients
113
Services billed
5,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo15$724,599
XolairOmalizumab35$134,341
IcatibantIcatibant Acetate13$116,008
Dupixent SyringeDupilumab22$82,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,311
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$22,383
Advair HfaFluticasone Propion/Salmeterol51$19,772
Arnuity ElliptaFluticasone Furoate60$15,754
Breo ElliptaFluticasone/Vilanterol24$12,745
AlvescoCiclesonide13$8,621
Incruse ElliptaUmeclidinium Bromide15$7,661
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$6,115
Epinephrine32$4,707
Levocetirizine Dihydrochloride67$2,308
Albuterol Sulfate HfaAlbuterol Sulfate92$1,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$780$724,59915 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta$1,841$59,471124 claims
AstraZenecaBreztri Aerosphere$6,785$22,38332 claims
Covis Pharma GmbHAlvesco$150$8,62113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 allergy providers in Massachusetts.

Other allergy in Milford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →